By Cocer Peptides 
15 days ago
ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE SOLELY FOR INFORMATION DISSEMINATION AND EDUCATIONAL PURPOSES.
The products provided on this website are intended exclusively for in vitro research. In vitro research (Latin: *in glass*, meaning in glassware) is conducted outside the human body. These products are not pharmaceuticals, have not been approved by the U.S. Food and Drug Administration (FDA), and must not be used to prevent, treat, or cure any medical condition, disease, or ailment. It is strictly prohibited by law to introduce these products into the human or animal body in any form.
Overview
Mazdutide is a novel drug that acts as a dual agonist of the glucagon-like peptide-1 (GLP-1) and glucagon receptors. GLP-1 and glucagon receptors play important roles in metabolic regulation in the human body. GLP-1 is primarily secreted by L cells in the intestine, released after meals, and stimulates insulin secretion in a glucose concentration-dependent manner while inhibiting glucagon secretion, thereby lowering blood glucose levels. GLP-1 also slows gastric emptying, increases satiety, and reduces food intake, thereby aiding in weight management. Glucagon receptors primarily regulate blood glucose balance. After glucagon binds to its receptor, it activates a series of signal transduction pathways to promote glycogenolysis and gluconeogenesis, thereby increasing blood glucose levels. Mazdutide, as a dual agonist, achieves metabolic regulation through a clever synergistic mechanism.
Mechanism of Action
Blood Glucose Regulation Mechanism
Promoting Insulin Secretion: After binding to the GLP-1 receptor, Mazdutide activates downstream signaling pathways, including the cAMP-PKA signaling pathway. Activation of this pathway enhances the sensitivity of pancreatic β-cells to glucose, leading to upregulation of insulin gene expression and increased insulin synthesis and secretion. When blood glucose levels rise, Mazdutide can more effectively stimulate insulin release, thereby lowering blood glucose levels. In patients with type 2 diabetes, Mazdutide increases postprandial insulin secretion through this mechanism, helping to maintain stable blood glucose levels.
Inhibition of glucagon secretion: Mazdutide's action on glucagon receptors also influences glucagon secretion. By binding to glucagon receptors, it inhibits signal transduction within pancreatic α cells, reducing glucagon synthesis and release. This inhibits glycogenolysis and gluconeogenesis, reducing glucose production at the source and further assisting in lowering blood glucose levels. This dual regulation of insulin and glucagon secretion gives Mazdutide a significant advantage in blood glucose regulation, enabling more precise control of blood glucose levels and avoiding large fluctuations.
Percent change from baseline in body weight over time. Proportion of participants reaching weight loss targets.
Weight management mechanism
Appetite regulation: Mazdutide binds to GLP-1 receptors, activating neurons in the hypothalamic appetite regulation center. These neurons participate in the transmission of satiety signals, and Mazdutide's action enhances these signals, thereby reducing food intake. It may also influence the secretion of gastrointestinal hormones, such as ghrelin, further regulating appetite. In clinical trials, participants using Mazdutide reported reduced appetite and decreased daily food intake, leading to weight loss.
Increasing energy expenditure: Mazdutide may also promote weight loss by influencing the body's energy metabolism. Research suggests it may activate brown adipose tissue, increasing its thermogenic activity. Brown adipose tissue is rich in mitochondria and can consume energy through non-shivering thermogenesis. Mazdutide may regulate related signaling pathways to promote the differentiation and activation of brown adipocytes, enhancing their thermogenic capacity, thereby increasing the body's energy expenditure and achieving weight loss. Mazdutide may also influence the metabolism of white adipose tissue, promoting the conversion of white fat to brown fat, further optimizing fat metabolism and reducing fat accumulation.
Uric acid regulation mechanism
Gene expression regulation: In studies using a rat model of hyperuricemia, significant changes in the expression of certain key genes were observed following Mazdutide intervention. These changes in gene expression may achieve a reduction in uric acid levels by regulating the precursors of uric acid synthesis and participating in processes such as glycolipid metabolism and purine metabolism. Upregulated genes promote uric acid excretion or participate in metabolic pathways that inhibit uric acid synthesis, while downregulated genes reduce the synthesis of precursors for uric acid synthesis, thereby comprehensively lowering serum uric acid levels.
Metabolic pathway regulation: Analysis of renal transcriptomics revealed that Mazdutide intervention significantly enriched KEGG pathways including bile secretion, the renin-angiotensin system, histidine metabolism, platinum resistance, hematopoietic cell lineages, complement, and the coagulation cascade. Regulation of these pathways may indirectly influence uric acid metabolism. Regulation of the bile secretion pathway may affect bile acid metabolism, which is closely related to lipid metabolism. Changes in lipid metabolism may in turn affect uric acid production and excretion. Regulation of the renin-angiotensin system may affect renal hemodynamics and tubular function, thereby influencing uric acid reabsorption and excretion.
Efficacy
Glucose Control Effect
In a randomized, double-blind, placebo-controlled Phase 2 clinical trial in patients with type 2 diabetes, Mazdutide demonstrated significant blood glucose control effects. The study randomly assigned adult patients with type 2 diabetes to receive 3 mg, 4.5 mg, or 6 mg of Mazdutide, 1.5 mg of open-label dulaglutide, or placebo, and administered subcutaneous injections for 20 weeks. Results showed that from baseline to week 20, the mean change in hemoglobin A1c (HbA1c) in the Mazdutide groups ranged from -1.41% to -1.67%, while the dulaglutide group had a change of -1.35% and the placebo group had a change of 0.03%. Compared with the placebo group, the changes in HbA1c levels in all Mazdutide dose groups were statistically significant (all P < 0.0001). This indicates that Mazdutide is significantly more effective than placebo in lowering HbA1c levels in patients with type 2 diabetes, and is comparable to or even superior to dulaglutide. The reduction in HbA1c levels reflects Mazdutide's ability to effectively improve long-term glycemic control in patients, thereby reducing the incidence of diabetic chronic complications.
Weight loss effects
Mazdutide demonstrates significant efficacy in weight management. In studies targeting overweight or obese adults, 24 weeks of Mazdutide treatment showed good weight loss effects. Overweight adults (body mass index [BMI] ≥24 kg/m²) with polyphagia and/or at least one obesity-related comorbidity, or obese adults (BMI ≥28 kg/m²), were randomly assigned (3:1:3:1:3:1) to receive weekly Mazdutide 3mg, 4.5mg, 6mg, or matched placebo treatment. Results showed that from baseline to week 24, the mean percentage change in weight was -6.7% (standard error 0.7) in the Mazdutide 3 mg group, -10.4% (0.7) in the 4.5 mg group, -11.3% (0.7) in the 6 mg group, and 1.0% (0.7) in the placebo group. Compared with placebo, the treatment differences for Mazdutide across all dose groups ranged from -7.7% to -12.3% (all P < 0.0001). This indicates that Mazdutide can significantly reduce body weight in overweight or obese adults in a dose-dependent manner. This weight loss not only helps improve patients' physical appearance but more importantly reduces the risk of various obesity-related diseases, such as cardiovascular disease and diabetes.
Uric acid-lowering effect
In a rat model of hyperuricemia, Mazdutide demonstrated good uric acid-lowering effects. Hyperuricemia was induced in rats by oral administration of adenine and potassium oxinic acid, followed by treatment with different doses of Mazdutide. The results showed that the medium- and high-dose groups of Mazdutide (0.05 mg/kg and 0.075 mg/kg, administered via subcutaneous injection every 3 days) significantly reduced serum uric acid (SUA) levels in rats. Mazdutide also improved kidney function, reduced serum creatinine (SCr) and urine protein (U-Pro) levels, and improved renal tissue pathology. This suggests that Mazdutide not only reduces serum uric acid levels but also has a protective effect against kidney damage caused by hyperuricemia.
Application Areas
Treatment of Type 2 Diabetes
Given Mazdutide's significant efficacy in blood glucose control, it holds great potential for application in the treatment of type 2 diabetes. Currently, the treatment of type 2 diabetes primarily relies on the combination of multiple medications to control blood glucose levels and prevent the occurrence of complications. As a novel dual receptor agonist, Mazdutide's unique mechanism of action enables it to regulate glucose metabolism at multiple levels, offering a new treatment option for patients with type 2 diabetes. Compared to traditional antidiabetic drugs, Mazdutide not only effectively lowers blood glucose levels but also offers the benefit of weight reduction, which is particularly important for most type 2 diabetes patients who are overweight or obese.
Obesity and overweight management
Obesity and overweight have become global public health issues closely associated with the onset of various chronic diseases. Mazdutide's significant effects in weight management make it a potential therapeutic option for obese and overweight individuals. By regulating appetite and increasing energy expenditure, Mazdutide can help obese and overweight patients lose weight and improve their metabolic status. Compared to traditional weight loss methods such as dieting and exercise, Mazdutide offers a more effective adjunctive treatment option, particularly for those who struggle to achieve their ideal weight through lifestyle interventions. Additionally, due to its mechanism of action involving multiple physiological regulatory processes, Mazdutide may have positive effects on the cardiovascular and metabolic systems while reducing weight, thereby lowering the risk of obesity-related complications.
Conclusion
In summary, as a novel dual agonist of GLP-1 and glucagon receptors, Mazdutide demonstrates unique mechanisms of action and significant efficacy in blood glucose regulation, weight management, and potential uric acid regulation, playing a crucial role in the management of type 2 diabetes, obesity, and overweight conditions.
Sources
[1] Zhang B, Cheng Z, Chen J, et al. Efficacy and Safety of Mazdutide in Chinese Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial[J]. Diabetes Care, 2024,47(1):160-168.DOI:10.2337/dc23-1287.
[2] Nalisa D L, Cuboia N, Dyab E, et al. Efficacy and safety of Mazdutide on weight loss among diabetic and non-diabetic patients: a systematic review and meta-analysis of randomized controlled trials[J]. Frontiers in Endocrinology, 2024,15. https://api.semanticscholar.org/CorpusID:267984513
[3] Ji L, Jiang H, Cheng Z, et al. A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity[J]. Nature Communications, 2023,14(1):8289.DOI:10.1038/s41467-023-44067-4.
[4] Jiang H, Zhang Y, REN Y S. 77-LB: A Novel Glucagon-Like Peptide-1 (GLP-1R) and Glucagon (GCGR) Receptor Dual Agonist, Mazdutide (IBI362), Attenuates Hyperuricemia in Hyperuricemic Rats[J]. Diabetes, 2023. https://api.semanticscholar.org/CorpusID:259452040
Product available for research use only:
